Drugs / Disodium Pyrophosphate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04441671 | Dec 2020 → Apr 2021 | pseudoxanthoma elasticum (inherited or acquired) | Tampere University Hospital | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Disodium Pyrophosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04441671 ↗ |
| Route | Oral | “Phase II oral capsulized disodium-PPi (Na2H2PPi) powder absorption study” NCT04441671 ↗ |